No new clinical data or guidance change, the stock will trade on the unchanged PROACT 1 timeline (enrollment mid-2026, data Q2 2027). The updated 80% powering assumption for the surrogate endpoint is a minor technical clarification, not a de-risking event. Monitor for enrollment completion announcement in the coming months as the next catalyst.
PROK drugs
PROK drug pipeline →Price Chart
Executive Summary
ProKidney reported Q1 2026 financial results that were in line with consensus, with a net loss of $20.0M available to Class A common stockholders ($-0.14 EPS) versus the $-0.14 estimate. The company reiterated its key clinical milestones: Phase 3 PROACT 1 enrollment completion mid-2026 and pivotal eGFR slope data in Q2 2027. Cash burn accelerated to $41.7M in operating cash flow (vs $29.6M in Q1 2025), reducing the cash runway to $224.9M, still supporting operations into mid-2027. The filing is neutral, no new data, no guidance change, and the clinical timeline remains on track.
Key Financial Metrics
Key Facts
- Q1 2026 net loss available to Class A common stockholders was $20.0M ($-0.14 EPS), in line with consensus of $-0.14
- Revenue was $226K, essentially flat vs $230K in Q1 2025
- Cash, cash equivalents and marketable securities totaled $224.9M at March 31, 2026, down from $270.0M at December 31, 2025
- Operating cash flow was -$41.7M in Q1 2026 vs -$29.6M in Q1 2025, a 41% increase in cash burn
- Phase 3 PROACT 1 enrollment for accelerated approval efficacy analysis remains on track for mid-2026, with pivotal topline results expected Q2 2027
- The statistical powering assumption for the surrogate endpoint (eGFR slope) was updated to 80% (from prior 90%) in the 8-K Item 8.01
- Cash runway guidance unchanged: operations funded into mid-2027
Financial Impact
Q1 2026 net loss of $20.0M on $226K revenue; cash burn increased 41% YoY to $41.7M operating cash flow; cash position $224.9M provides runway into mid-2027
Risk Factors
- Cash burn accelerated to $41.7M/quarter, reducing runway faster than prior run-rate implied
- Phase 3 PROACT 1 trial failure risk remains binary, no interim data to de-risk
- No new financing announced; if enrollment or data timeline slips, the company may need to raise capital before mid-2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-225848 |
| Document: prok-20260515.htm | 0001193125-26-225848 |
| Document: prok-ex99_2.htm | 0001193125-26-225848 |
| Document: 0001193125-26-225848-index-headers.html | 0001193125-26-225848 |
| Document: 0001193125-26-225848-index.html | 0001193125-26-225848 |
| Document: 0001193125-26-225848.txt | 0001193125-26-225848 |
| 8-K Data (Synthetic) | 0001193125-26-225848 |
Track record
13 reports on PROK
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
- May 15, 202626w ago 8-K Neutral 4/10 Viewing No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers